(INNS)
TARPERPRUMIG(INND)
TARPERPRUMIG(INNC)
IMMUNOGLOBULIN SINGLE CHAIN VH-VH', ANTI-[HOMO SAPIENS ALB (ALBUMIN, HUMAN SERUM ALBUMIN, HSA)] AND ANTI-[HOMO SAPIENS CFP (COMPLEMENT FACTOR PROPERDIN, PROPERDIN)], HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC, BIVALENT; SINGLE CHAIN (SC) VH-VH' (1-256) [HUMANIZED VH ANTI- ALB (VICUGNA PACOS IGHV3-3*01 (81.6%) -(IGHD) - IGHJ3*01 (92.3%)/HOMO SAPIENS IGHV3-11*05 (80.4%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.7.17] (26-33.51-57.96-112) (1-123)) -14-MER BIS(TETRAGLYCYL-GLUTAMYL) TETRAGLYCYL LINKER (124-137) - HUMANIZED VH ANTI-CFP (VICUGNA PACOS IGHV3S53*01 (81.4%) -(IGHD) -IGHJ4*01, Q123>L (251) (92.3%)/HOMO SAPIENS IGHV3-23*01 (80.2%) - (IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.7.13] (163- 170.188-194.233-245) (138-256))], PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHOK1SV, NON-GLYCOSYLATED(WHO)
IMMUNOGLOBULIN SINGLE CHAIN VH-VH', ANTI-[HOMO SAPIENS CFP (COMPLEMENT FACTOR PROPERDIN, PROPERDIN)] AND ANTI-[HOMO SAPIENS ALB (ALBUMIN, HUMAN SERUM ALBUMIN, HAS)], HUMANIZED MONOCLONAL ANTIBODY, BISPECIFIC, BIVALENT; SINGLE CHAIN (SC) VH-VH' (1-256) [HUMANIZED VH ANTI- CFP (VICUGNA PACOS IGHV3-3*01 (81.6%) -(IGHD) - IGHJ3*01 (92.3%)/HOMO SAPIENS IGHV3-11*05 (80.4%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.7.17] (26-33.51-57.96-112) (1-123)) -15-MER TRIS(TETRAGLYCYL-GLUTAMYL) LINKER (124-138)-HUMANIZED VH ANTI-ALB (VICUGNA PACOS 3S3*01 (82.3%) -(IGHD) -IGHJ4*01, Q123>L (92.3%)/HOMO SAPIENS IGHV3- 23*01 (80.0%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.7.13] (163-170.188-194.233-245) (139-256))], PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, CELL LINE CHO-K1SV, NON-GLYCOSYLATED(WHOX)
TARPERPRUMIGUM(INN)